Lombard Medical Technologies (LMT) is a specialist cardiovascular device and polymer coatings company which focuses on discovering, developing and commercialising innovative products that address the unmet needs of medical professionals across the world.

 

LMT’s technological expertise results in products with design advantages over the competition.

 

Headquartered near Oxford, in the UK, LMT has made considerable progress with its flagship product – the Aorfix™ endovascular stent graft for Abdominal Aortic Aneurysm (AAA) disease.

 

Aorfix™  addresses a growing market forecast to exceed $1 billion by 2010. Its unique design incorporating durability, good fixation and unparalleled flexibility complies with the changing human anatomy and makes it suitable for the treatment of most AAA’s.

 

Aorfix™ endovascular stent graft is CE Mark approved in the EU and has obtained IDE approval from the FDA in connection with US clinical trials.

 

LMT’s Polymer Coatings Division concentrates on drug delivery polymers with PEP™ (programmable elution profile) technology that allows several drugs to be released from a coating at different times and in different quantities. This technology is being used with partners from academia and the pharmaceutical industry to develop potential new coatings for drug eluting coronary stents.

 

Updated September 2008

 


LSE Share Price

   Connecting